Q&A: Parkland's Incoming Interim CEO on Problem Solving
Q. How did you come to be named as Parkland's new interim CEO?
A. I was with Tenet Healthcare for quite a while and retired last year. I told a number industry contacts that I would be interested in working on assignments on an interim basis. One of those contacts was involved in some of the turnaround process here at Parkland and encouraged the board chair [Debbie Branson] to contact me. I spoke with the chair and some of the individual board members.
My agreement starts on Sept. 1 but I won't be on site yet. I will be doing a series of orientation calls to make sure that once I am physically here I will be up to speed.
Q. What authority will you have to resolve the problems at Parkland?
A. I think the board views me as the CEO on an interim basis. With the exception of hiring and terminating individuals in the executive ranks I will have full authority to continue the work that's underway and to make the changes that are necessary. I just won't be making high level executive changes without board involvement. No CEO would.
Q. You're credited with turning around Tenet's central states region. What problems did you face?
A. Facilities were going through leadership changes as a result of problems within Tenet. There was a lot of turnover among hospital and corporate executives. When I came on in 2003 I dealt with talent management and talent placement as a means to affect a change in the overall operation of the region. I put new leadership in place and refashioned the executive talent at the facilities. It took several years to get that in place.
- How Top-Ranked MA Plans Earn Their Stars
- Readmissions: No Quick Fix to Costly Hospital Challenge
- How Hospitals Can Become 'Upstreamists'
- 4 Ways to Lower the Cost to Collect from Self-Pay Patients
- House Calls Key to Pioneer ACO Success
- How Telehealth Pays Off for Providers, Patients
- 4 Tips for Managing Employed Physicians
- Defensive Medicine Still Prevalent Despite Tort Reform
- WellPoint Dominates Nearly Half of Markets, AMA Says
- 'Overtreatment' Debate Circles Back to Lung Cancer Screening